Brief: Cantargia Reports Similar Efficacy For Its Drug And Chemo In Trial

Cantargia AB

18/07/2025 06:37

July 18 (Reuters) - Cantargia AB CANTA.ST:

SAID ON THURSDAY IT ANNOUNCED PRELIMINARY TOPLINE RESULTS FROM PHASE 2 TRIFOUR TRIAL IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER

SAYS PRIMARY ENDPOINT, OVERALL RESPONSE RATE (ORR), WAS SIMILAR IN THE NADUNOLIMAB PLUS CHEMOTHERAPY GROUP (40%) AND THE CHEMOTHERAPY REFERENCE GROUP (43%)

STATES THE DRUG WAS WELL TOLERATED AND DID NOT IMPACT THE SAFETY PROFILE OF THE CHEMOTHERAPY

CEO SAYS THE COMPANY NOW AWAITS MATURE SURVIVAL DATA AND WILL UNDERTAKE A DETAILED PORTFOLIO DISCUSSION

 Source text for Workspace: nMFN3v2fd6
 Further company coverage: CANTA.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))